{
    "title": "114_hr639",
    "content": "The Act titled \"Improving Regulatory Transparency for New Medical Therapies Act\" amends the Federal Food, Drug, and Cosmetic Act to delay drug approval until an interim final rule controlling the drug is issued under the Controlled Substances Act. The Act \"Improving Regulatory Transparency for New Medical Therapies Act\" delays drug approval until an interim final rule controlling the drug is issued under the Controlled Substances Act, specifying the date of approval for applications and biological products. The Secretary notifies the sponsor of intent to issue a scientific evaluation and recommend controls under the Controlled Substances Act. Approval of the application is delayed until the interim final rule for the biological product is issued. The date of approval is the later of the application approval or the issuance of the interim final rule. The approval of animal drugs under the Controlled Substances Act is delayed until the interim final rule is issued. The date of approval is determined by the later of the application approval or the issuance of the interim final rule. The date of approval for animal drugs under the Controlled Substances Act is determined by the later of the application approval or the issuance of the interim final rule. Conditional approval is subject to the issuance of the interim final rule controlling the drug. The Controlled Substances Act determines the date of approval for animal drugs based on the later of conditional approval or the issuance of the interim final rule. Additionally, the indexing of legally marketed unapproved new animal drugs is addressed in the Federal Food, Drug, and Cosmetic Act. The Secretary will issue a scientific and medical evaluation and recommend controls under the Controlled Substances Act. Approval for designated new animal drugs will not take effect until the interim final rule controlling the drug is issued. The interim final rule controlling the drug is issued under the Controlled Substances Act, with the Secretary recommending scheduling of newly approved drugs within 90 days. The Attorney General issues an interim final rule under the Controlled Substances Act based on recommendations from the Secretary of Health and Human Services regarding newly approved drugs. The rule becomes immediately effective without needing a demonstration of good cause and allows for public comment and hearing opportunities. The Attorney General issues a final rule under the Controlled Substances Act based on recommendations from the Secretary of Health and Human Services for newly approved drugs. The rule is issued after public comment and hearing opportunities. Amendments are made to Section 156 of title 35, United States Code, regarding the extension of patent terms for drug products. The Secretary intends to recommend controls under the Controlled Substances Act for newly approved drug products, which will be considered approved under relevant provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act upon the covered date. The covered date is defined as the date of application approval or conditional approval under specific sections of the mentioned acts. SEC. 3. ENHANCING NEW DRUG DEVELOPMENT.\n    Section 303 of the Controlled Substances Act (21 U.S.C. 823) is \namended to expedite registration for manufacturing controlled substances for clinical trials, ensuring approval within 180 days of application acceptance. The Attorney General must issue a notice of application within 90 days of acceptance, and register the applicant within 90 days after the comment period ends. Re-exportation among members of the European Economic Area is amended in the Controlled Substances Import and Export Act. The Controlled Substances Import and Export Act is amended to allow re-exportation of controlled substances among European Economic Area countries, with specific conditions to be met by each subsequent country involved. The Controlled Substances Import and Export Act is amended to allow re-exportation of controlled substances among European Economic Area countries, with specific conditions to be met by each subsequent country involved. Re-exportation documentation and information must be provided within 30 days after each re-exportation. The Controlled Substances Import and Export Act is amended to allow re-exportation of controlled substances among European Economic Area countries without restrictions on time or information disclosure. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}